Stock Taper
SCREENER COMPARE ANY 2 STOCKS
MIRA
MIRA PHARMACEUTICALS, INC.
NASDAQ
$0.75
▼ DOWN 2.60% (-0.02)

KEY STATISTICS

Market Cap$31.52 M
52w High$2.45
52w Low$0.60
Dividend Yield—
Frequency—
P/E-0.52
Volume31.85K
Shares Out.42.02M

COMPANY

LEADERSHIP

Erez Aminov
CHIEF EXECUTIVE
Erez Aminov

COMPENSATION 2026

Salary$438,750
Stock Awards$184,375
Incentive Plan Pay$0
All Other Comp.$19,674
Total$5,304,174

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 3, 2023
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
2

UPCOMING EARNINGS

DateDec 2, 2026
DayWednesday
Rev. Est.—
DEC
2
WED

PRICE

$0.75 ▼ DOWN 2.60% (−$0.02)
$0.75$0.76$0.769:58 AM10:58 AM11:58 AM12:59 PM1:59 PM2:59 PM3:59 PM0.75

About MIRA Pharmaceuticals, Inc.

https://mirapharmaceuticals.com ↗

MIRA Pharmaceuticals, Inc., a Baltimore-based clinical-stage biopharmaceutical company founded in 2020, develops synthetic THC analogs like MIRA1a to treat anxiety, cognitive decline, and chronic pain associated with early-stage dementia.

INDUSTRY

Drug Manufacturers - General

A PRODUCT MIRA PHARMACEUTICALS, INC. IS KNOWN FOR

Ketamir-2
Ketamir-2

Ketamir-2, MIRA Pharmaceuticals' lead oral drug candidate, is in late-stage Phase 1 trials for neuropathic, inflammatory, metabolic, and oncology pain conditions, with plans to progress to Phase 2a.

COMPETITORS

COMPETITOR
ACAD COMPARE
ATAI COMPARE
NRXP COMPARE
RLMD COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
12
LISTED HERE
2
RANKED BY POSITION SIZE
VTS.AX
0.00% · 394.1K
IWC
0.01% · 128.3K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
5.13%
HOLDERS
34
TOP 12 OF 34 · RANKED BY POSITION SIZE
Vanguard Group Inc
660.5K sh · $997.35K
Cross Staff Investments Inc
359.4K sh · $384.56K
Mirae Asset Global Etfs Holdings Ltd.
312.8K sh · $472.29K
Geode Capital Management, LLC
290.9K sh · $311.25K
Blackrock, Inc.
112.3K sh · $120.21K
Suncoast Equity Management
103.3K sh · $140.47K
Northern Trust Corp
67.7K sh · $72.44K
First American Bank
60.0K sh · $64.2K
State Street Corp
49.1K sh · $74.14K
Renaissance Technologies LLC
46.7K sh · $63.51K
Two Sigma Investments, LP
45.7K sh · $62.16K
J.W. Cole Advisors, Inc.
45.5K sh · $61.88K

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book2
Overall Score1

INSIDER TRADES

★
DIRECTOR
Whalen Matthew Pratt
Purchase · 50.0K shares
2026-06-12
★
DIRECTOR
Del Giudice Matthew Paul
Purchase · 50.0K shares
2026-06-12
★
DIRECTOR
MacPherson Edward Clouston
Purchase · 50.0K shares
2026-06-12
★
DIRECTOR
Shekhat Denil Nanji
Purchase · 50.0K shares
2026-06-12

SECTORS PEERS

PEERPRICE
QTTB$15.03COMPARE
ANTX$5.58COMPARE
TLPH$1.20COMPARE
MYO$1.60COMPARE
POCI$4.40COMPARE
MODD$3.46COMPARE